These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30285636)

  • 1. Comparing survival functions with interval-censored data in the presence of an intermediate clinical event.
    Kim S; Kim J; Nam CM
    BMC Med Res Methodol; 2018 Oct; 18(1):98. PubMed ID: 30285636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A generalized log-rank-type test for comparing survivals with doubly interval-censored data.
    Kim J; Kim YJ; Nam CM
    Biom J; 2009 Aug; 51(4):689-96. PubMed ID: 19650058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A generalized log-rank test for interval-censored failure time data via multiple imputation.
    Huang J; Lee C; Yu Q
    Stat Med; 2008 Jul; 27(17):3217-26. PubMed ID: 18254128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weighted logrank tests for interval censored data when assessment times depend on treatment.
    Fay MP; Shih JH
    Stat Med; 2012 Dec; 31(28):3760-72. PubMed ID: 22786795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.
    Lakomy R; Poprach A; Bortlicek Z; Melichar B; Chloupkova R; Vyzula R; Zemanova M; Kopeckova K; Svoboda M; Slaby O; Kiss I; Studentova H; Juracek J; Fiala O; Kopecky J; Finek J; Dusek L; Hejduk K; Buchler T
    BMC Cancer; 2017 Dec; 17(1):880. PubMed ID: 29268716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partitioned log-rank tests for the overall homogeneity of hazard rate functions.
    Liu Y; Yin G
    Lifetime Data Anal; 2017 Jul; 23(3):400-425. PubMed ID: 26995734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
    Chen CC; Hess GP; Liu Z; Gesme DH; Agarwala SS; Garay CC; Hill JW; Guo A
    Clin Genitourin Cancer; 2012 Dec; 10(4):256-61. PubMed ID: 22682982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study.
    Kucharz J; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Herman RM; Krzemieniecki K
    Tumori; 2015; 101(5):555-9. PubMed ID: 26045121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival.
    Conlon AS; Taylor JM; Sargent DJ; Yothers G
    Clin Trials; 2011 Oct; 8(5):581-90. PubMed ID: 21921063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
    Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
    J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity analysis for missing outcomes in time-to-event data with covariate adjustment.
    Zhao Y; Saville BR; Zhou H; Koch GG
    J Biopharm Stat; 2016; 26(2):269-79. PubMed ID: 25635808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials.
    Molina AM; Lin X; Korytowsky B; Matczak E; Lechuga MJ; Wiltshire R; Motzer RJ
    Eur J Cancer; 2014 Jan; 50(2):351-8. PubMed ID: 24051327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
    Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
    J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consistent estimation of the expected Brier score in general survival models with right-censored event times.
    Gerds TA; Schumacher M
    Biom J; 2006 Dec; 48(6):1029-40. PubMed ID: 17240660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
    Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.